Jubilant Life Sciences’ arm inks term sheet to market Technegas in United States

14 Sep 2015 Evaluate

Jubilant Life Sciences’ wholly-owned subsidiaries, Jubilant DraxImage Inc. (DraxImage) has signed a term sheet, subject to satisfactory due diligence and execution of the Definitive Agreement and other necessary approvals, with Cyclopharm (CYC), providing DraxImage an exclusive license to market and distribute Technegas in the United States.

DraxImage will assist CYC with the development and financing of the phase III clinical trials for Technegas, and any other steps required to file for and obtain USFDA approval. Technegas is an imaging agent primarily used in Pulmonary Embolism (blockage of lung arteries) and is currently being sold in 55 countries including EU, Japan and Canada by CYC.

Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Specialty Pharmaceuticals and Life Science Ingredients.


Jubilant Pharmova Share Price

1040.35 -9.05 (-0.86%)
30-Dec-2025 11:44 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.50
Dr. Reddys Lab 1268.00
Cipla 1486.80
Zydus Lifesciences 901.55
Lupin 2075.30
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×